一分钟看懂
这是一项关于肉瘤的II 期研究，登记的药物或干预包括Toripalimab；Liposomal doxorubicin；Stereotactic body radiotherapy (SBRT)，当前状态为尚未开始招募。登记地点显示中国天津有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Toripalimab；Liposomal doxorubicin；Stereotactic body radiotherapy (SBRT) · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Tianjin Medical University Cancer Institute & Hospital · 天津
公开的入选条件
- Inclusion Criteria:
- 1. Male or female, aged 18 to 75 years.
- 2. Histologically confirmed UPS, screened locally and confirmed by central pathology before enrollment. Adequate IHC (at least CK, S100, SOX10, SMA, desmin, MDM2, CDK4) and NGS when feasible (MDM2/CDK4 amplification mandatory) to exclude dedifferentiated lipos
- 3. UPS of extremities or trunk. Max diameter \>5 cm, or \<=5 cm with any of: encasement of major neurovascular bundle \>180 degrees; expected limb functional loss \>50% after resection; MDT deems R0 difficult. SBRT-feasible anatomy with \>3 mm margin to critic
- 4. Regional nodes evaluated by imaging (US/CT/MRI/PET-CT). Suspicious nodes (short axis \>=10 mm, abnormal morphology, or high FDG) require pathology. Uninvolved nodes must not be irradiated; involved nodes included with radical dose or resected.
- 5. Treatment-naive: no prior chemotherapy, targeted therapy, immunotherapy, or local radiotherapy.
- 6. At least one measurable lesion per RECIST v1.1.
- 7. ECOG 0-1.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07817095；登记信息更新于 2026-09-14。